Bayer’s Turnaround Test: Supreme Court Win Sets Up a Pivotal July and August for the Leveraged Giant
Veröffentlicht: 30.06.2026 um 06:05 Uhr, Redaktion boerse-global.de
The stock has roughly doubled from its lows of last summer, but the rally now faces two make-or-break events within a month. Bayer shares traded at €45.39 on Tuesday, a 2.62% pullback after a 19.42% surge in the week following the US Supreme Court’s June 25 ruling that gutted the legal basis for thousands of Roundup claims. The gain over the past twelve months stands at 77.51%, and the stock briefly touched €49.93 earlier in the cycle. Yet the relative strength index has climbed into overbought territory—73.8 on the secondary article’s measure, 76.2 in another—suggesting the rally is getting stretched even as the company’s fundamental challenges remain unresolved.
The Supreme Court decision is an undeniable win, but it does not close the Monsanto chapter. A class-action settlement worth up to $7.25 billion still awaits final approval at a hearing on July 9 in Missouri. If the judge signs off, a major overhang dissolves. If the hearing stalls or the court imposes conditions, the uncertainty that has dogged Bayer for years will persist. Meanwhile, CEO Bill Anderson has warned that Bayer could halt US glyphosate production if it cannot secure lasting legal protection.
Anderson and his new chief financial officer, Judith Hartmann, are operating with one hand tied behind their backs. Net financial debt stood at €32.518 billion at the end of March and is projected to rise to as much as €33 billion by year-end. The company expects litigation costs of roughly €5 billion in 2026—money that would otherwise be earmarked for R&D, bolt-on acquisitions, or debt reduction. To conserve cash, Bayer slashed its dividend to the statutory minimum of €0.11 per share.
Should investors sell immediately? Or is it worth buying Bayer?
The bull case hinges on operating momentum finally getting the attention it deserves. The Crop Science division has held up well, while pharmaceutical assets such as Nubeqa and Kerendia are delivering strong growth. The recent acquisition of Perfuse Therapeutics bolsters the pipeline in ophthalmology. Anderson has been driving an internal efficiency push aimed at cutting bureaucracy and flattening structures. If that programme gains traction and the legal costs begin to recede, earnings power could improve markedly. On that trajectory, the stock’s previous annual high of €49.93 becomes a near-term target.
The bear case is not hard to sketch. Even after the Supreme Court victory, unresolved cases around the toxic chemical PCB continue to hang over the group. A separate US trade investigation into German drug pricing, launched in June, could lead to tariffs or tighter price controls on Bayer’s pharmaceutical sales in its largest market—a risk that appears barely priced in. And the management’s refusal to consider a breakup or a spin-off of Monsanto is straining relations with a vocal group of investors who see more value in a leaner structure.
The next hard catalyst is July 9, when the Missouri court rules on the class-action settlement. The one after that is August 4, when Bayer releases its half-year report. Investors will demand concrete evidence that the legal win is translating into a measurable reduction in net debt. For a company whose share price has already priced in a good deal of relief, the margin for disappointment is thin.
Ad
Bayer Stock: New Analysis - 30 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
